DrugPatentWatch Database Preview
Sofosbuvir - Generic Drug Details
What are the generic sources for sofosbuvir and what is the scope of sofosbuvir patent protection?
Sofosbuvir
is the generic ingredient in three branded drugs marketed by Gilead Sciences Inc and is included in three NDAs. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sofosbuvir has three hundred and twenty-one patent family members in forty-seven countries.
There are nine drug master file entries for sofosbuvir. One supplier is listed for this compound.
Summary for sofosbuvir
| International Patents: | 321 |
| US Patents: | 18 |
| Tradenames: | 3 |
| Applicants: | 1 |
| NDAs: | 3 |
| Drug Master File Entries: | 9 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 67 |
| Clinical Trials: | 265 |
| Patent Applications: | 196 |
| Formulation / Manufacturing: | see details |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for sofosbuvir |
| DailyMed Link: | sofosbuvir at DailyMed |
Pharmacology for sofosbuvir
| Drug Class | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor |
| Mechanism of Action | RNA Replicase Inhibitors |
Medical Subject Heading (MeSH) Categories for sofosbuvir
Synonyms for sofosbuvir
| (S)-2-{[(1R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-(R)-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy]phenoxyphosphorylamino}propionic acid (S)-isopropyl ester |
| (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate |
| 1064684-44-1 |
| 1190307-88-0 |
| 1221574-17-9 |
| 1421833-87-5 |
| 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester |
| AB0109660 |
| AC-27382 |
| AKOS024464753 |
| AKOS025401925 |
| AM84279 |
| AMMD00019 |
| AMX10213 |
| AOB6269 |
| AS-19600 |
| C22H29FN3O9P |
| CHEBI:85083 |
| CHEMBL1258950 |
| CHEMBL1259059 |
| CHEMBL3186678 |
| CS-0554 |
| D10366 |
| DA-47516 |
| DB08934 |
| EX-A389 |
| GI 7977 |
| GI-7977 |
| GS 7977 |
| GS-7977 |
| GS-9851 |
| GTPL7368 |
| Hepcinat |
| Hepcvir |
| HSDB 8226 |
| HY-15005 |
| isopropyl ((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate |
| isopropyl ((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate |
| isopropyl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate |
| isopropyl (2S)-2-[[[(3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyl-tetrahydrofuran-2-yl]methoxy-phenoxy-phosphoryl]amino]propanoate |
| isopropyl (2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate |
| KB-80152 |
| L-Alanine, N-((2'R)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl)-, 1-methylethyl ester |
| L-Alanine, N-((P(S),2'R)-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl)-, 1-methylethyl ester |
| MolPort-028-720-482 |
| MolPort-028-720-483 |
| N-((2'R)-2'-Deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl)-L-alanine 1-methylethyl ester |
| propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate |
| Propan-2-yl (2S)-2-{[{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate (non-preferred name) |
| psi 7851 |
| PSI 7977 |
| PSI-7851 |
| PSI-7977 |
| Q-4112 |
| QC-10465 |
| Resof |
| S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4- dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)- (phenoxy)phosphorylamino)propanoate |
| s2794 |
| SB20304 |
| SC-87382 |
| SCHEMBL18061557 |
| SCHEMBL2003999 |
| SCHEMBL2010114 |
| Sofosbuvir (JAN/USAN) |
| Sofosbuvir (PSI-7977, GS-7977) |
| Sofosbuvir [USAN:INN] |
| Sofosbuvir pound PSI7977 GS-7977 pound(c) |
| Sofosbuvir(PSI-7977) |
| SOVALDI |
| Sovaldi (TN) |
| SoviHep |
| SW219116-1 |
| UNII-3S5S1851OV component TTZHDVOVKQGIBA-IQWMDFIBSA-N |
| UNII-3S5S1851OV component TTZHDVOVKQGIBA-YBSJRAAASA-N |
| UNII-WJ6CA3ZU8B |
| WJ6CA3ZU8B |
| Y1293 |
| ZINC100074252 |
US Patents and Regulatory Information for sofosbuvir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | SOVALDI | sofosbuvir | TABLET;ORAL | 204671-001 | Dec 6, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-001 | Jun 28, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-001 | Jun 28, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | SOVALDI | sofosbuvir | TABLET;ORAL | 204671-001 | Dec 6, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Gilead Sciences Inc | SOVALDI | sofosbuvir | TABLET;ORAL | 204671-001 | Dec 6, 2013 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Gilead Sciences Inc | EPCLUSA | sofosbuvir; velpatasvir | TABLET;ORAL | 208341-001 | Jun 28, 2016 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for sofosbuvir
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2682230 | ➤ Sign Up |
| Ecuador | SP12012282 | ➤ Sign Up |
| Japan | 2015028060 | ➤ Sign Up |
| China | 104039319 | ➤ Sign Up |
| Israel | 222810 | ➤ Sign Up |
| Australia | 2012346217 | ➤ Sign Up |
| Peru | 10562014 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for sofosbuvir
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2203462 | 14C0082 | France | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894/001-002 20140117 |
| 2203462 | 122014000108 | Germany | ➤ Sign Up | PRODUCT NAME: SOVALDI (SOFOSBUVIR); NAT. REGISTRATION NO/DATE: EU /1/13/894 20140116; FIRST REGISTRATION: EU EU/1/13/894 20140116 |
| 2203462 | C20140035 00135 | Estonia | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014 |
| 2203462 | 67/2014 | Austria | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117 |
| 2203462 | 2014029 | Norway | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR. (S)-ISOPROPYL 2-; NAT. REG. NO/DATE: EU/1/13/894 20140116; FIRST REG. NO/DATE: (001-002) 20140117 |
| 2203462 | C02203462/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: SWISSMEDIC 63218 18.03.2014 |
| 2203462 | CA 2014 00061 | Denmark | ➤ Sign Up | PRODUCT NAME: SOFOSBUVIR; REG. NO/DATE: EU/1/13/894/001-002 20140116 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2019 - 2020
NCE-1 Generic Application Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.
Follow DrugPatentWatch: